HeartWare International — Canaccord Genuity Medical Technologies and Diagnostics Forum 2015
25 slides from HeartWare International's conference presentation, Nov 19, 2015

Slide 1: HeartWare
Exhibit 99.1 HeartWare®

Slide 2: Canaccord Genuity Medical Technologies and Diagnostics Forum
Canaccordtrademarks registered Genuity Medical of HeartWare. Technologies HeartWare® and Diagnostics Forum November 19, 2015 · New York, NY DOUG GODSHALL PRESIDENT AND CEO HEARTWARE, HVAD and the HEARTWARE logo are

Slide 3: Forward-Looking Statements
SafeExchange currently without regulatory technology. only except disclosed number Commission. and Harbor asas of of limitation available may in the and risks Management forward-looking Statement HeartWare date Commission. be quality and required our when touncertainties, management. expectations co

Slide 4: Additional Information and Participants in Solicitation
Additional employees officers information indirect with that definitive (when The addition, Connecticut securities, jurisdiction. HVAD contains proxy the they and is interests SEC investors proxy set nor statement/prospectus may Shareholder the become regarding No Path, aforth on shall preliminary H

Slide 5: Mission and HVAD System Proven Track Record
Mission CE Safe Mark HeartWare® We 2012: create FDA 5revolutionary Approval ~125 technology U.S. Centers for the~180 treatment Intl. Centers of heartHVAD® failure toSystem—A allow patients Proven to get Track backRecord to life.HEARTWARE, Note: Data as ofHVAD November and the 2, 2015. HEARTWARE 9,00

Slide 6: Enabling Patients to Get Back to Life
Enabling Patients to Get Back to Life HEARTWARE, HVAD and the HEARTWARE logo are registered trademarks of HeartWare. Safe HeartWare® 6

Slide 7: HeartWare HVAD System
HeartWare® continuous CAUTION: Adverse Events flow Federal Ventricular and • Hybrid Instructions LawAssist (USA) magnetic System restricts prior / hydrodynamic toHVAD® using this device this System device. impeller to sale Miniaturized HEARTWARE, by suspension or on the Implantable order • Optimizes

Slide 8: Global HVAD Sales Growth
Global1,099 1,012 HeartWare. HVAD®Safe 232 Sales 432 HeartWare® 122 Growth; 332 292 8 6970 Units 110 165 in Q3 ‘09 Total ‘10 ‘11 Unit ‘12Sales: ‘13 ‘14 Int’l YTD& U.S. ‘14 YTD 3,000‘15 2,751 Data 2,500 as of2,183 September 2,079 1357 30, 2015 2,014 HEARTWARE, 2,000 1,084 1,500 HVAD1101 and1,002 the

Slide 9: Recent Milestones
Recent to in FDAMilestones U.S. •• Longest-supported Valtech’s •Cardioband® Announced HVAD agreement awarded patientCE reached to acquire Mark8approval years Valtech on•Cardio support Continued • HEARTWARE, Commenced ramping enrollment MVAD® HVADSystem in andHVAD® the CE HEARTWARE Mark LATERAL; inte

Slide 10: Pipeline Technology
PIPELINE TECHNOLOGY HEARTWARE, HVAD and the HEARTWARE logo are registered trademarks of HeartWare. Safe HeartWare®

Slide 11: MCS Pipeline: Maintaining Competitiveness
MCSare device Eliminates logo Portfolio Longhorn® registered driveline and trademarks •Pipeline: Tools Eliminates MVAD Maintaining ofoutflow HeartWare. Gimbalgraft and • Angle Safe Electronics Enhancing HeartWare® and depth Competitiveness Lavare adjustment 11• HVADThoracotomy pulsatility Pumps HVAD

Slide 12: The MVAD System
The MVAD® thoughtfully Investigators HeartWare. Safe designed Only. System HeartWare® CAUTION: Has peripherals Breakthrough 12Investigational to enhance Potential patient Device. • Small quality Limited size of enables life by MVAD® Federal less invasive (or Pump United PalTM implant States) Patient

Slide 13: qPulse Cycle
qPulse™ 120 Investigational 20k 18k Cycle 16kDevice. Customizable 14k 12kLimited 10k speed 8kbySpeed Federal adjustments (RPM) (or United Speed (3 settings) States) Aortic •Left law Designed to Ventricular investigational to promote Exclusively use. aortic HEARTWARE, for valve Clinical opening, Inve

Slide 14: MVAD CE Mark Trial
MVAD®• Implantation months Investigators HeartWare.Advantage™ Safe Only. HeartWare® CAUTION: via CEthoracotomy Mark 14Investigational Trial • or Multi-center, sternotomy Device. prospective, • First Limited patient bynon-randomized, Federal enrolled(or July United 2015 single-arm States) mVADlawAdva

Slide 15: MVAD Pump in situ
MVAD® United States) Pumplaw in situ to investigational SUPINE MOBILE use. HEARTWARE, Exclusively forHVAD Clinicaland Investigation. the HEARTWARE Investigational logo aredevice registered to betrademarks used by Qualified of HeartWare. Investigators Safe HeartWare® Only. CAUTION: 15 Investigational

Slide 16: MVAD System Commentary
MVAD® our return focus to the System to specific clinicCommentary HEARTWARE, areas within • Controller our HVAD manufacturing and assembly the HEARTWARE process, fix complete, whichlogo software we may are registered elect patchtoprogressing further trademarks tighten toward ofup HeartWare. submissi

Slide 17: Business Combination
BUSINESS COMBINATION HEARTWARE, HVAD and the HEARTWARE logo are registered trademarks of HeartWare. Safe HeartWare®

Slide 18: HeartWare + Valtech: Creating the Leader in Heart Failure and Mitral Disease
disease, customer, interventional HeartWare HeartWare. +Safe leadership Valtech: Nearer-term HeartWare® referral Creating in mitral channel commercial 18the replacement Technology and delivery opportunity Combined Leader system in established in pipeline will Heart create Failure creates surgical co

Slide 19: Covering the Spectrum of Heart Failure
Covering Mitral HeartWare® andthe Tricuspid 19 Spectrum Cardioband of Heart Failure Mitral and Heart Tricuspid Failure Continuum CardiovalveToday CircuLite Cardioband MVAD Mitral HVADHVAD Longhorn Tomorrow HEARTWARE, Cardinal Mitral HVADandandTricuspid the HEARTWARE Cardioband logo Mitral are regist

Slide 20: Our Mitral and Tricuspid Market Investment Thesis
Our Mitral approach needs therefore ventricular body Safe HeartWare® of repair evidence the • Annuloplasty and trauma and cardiologist’s Tricuspid replacement supporting 20 a watch-out the Market first most intervention Physicians •choice, Transseptal Investment frequently when Will • Tricuspid deli

Slide 21: Mitral Repair and Replacement Market Evolution
Replacement •proven Transapical Mostly• Broader reserved (TA), Will Phase use Transseptal for Eventually I:in high-risk Repair earlier+Have (TS). disease severe EarlyStrong HEARTWARE, TAFMR stages Replacement Place patients andinlower-risk the HVAD • Mature Phase Market; and patients II: transapical

Slide 22: Combined Portfolio Provides Leadership Position
Combined Source: HTWR Portfolio estimates. Provides HEARTWARE, Leadership Position HVAD in and Two theof HEARTWARE the Highest-Growth logo are Areas registered in Heart trademarks Failure 2015 of HeartWare. VAD 2030Safe ClassHeartWare® IV Class III22 $2.2B $800M $600M Valve Mitral Tricuspid $7.5B +1

Slide 23: Video Investor Meeting Slide Replay
Video Investor repeat opportunities are registered and hospitalization Meeting Slide A trademarks Vertically Replay Thursday, Most Available… of integrated patients November HeartWare. with For device 05, Safe more CHF 2015, company HeartWare® information have 9:00 FMR capable am and EST 23 andof in

Slide 24: Priorities for the Months Ahead
Priorities actions Complete clinic HEARTWARE, identified for follow-up the Months • Resume forHVAD ENDURANCE2 Ahead… enrollment and the • Advance HEARTWARE in DT CE trial discussions Mark• Secure clinical logowith are approval trialshareholders registered of MVAD in U.S. trademarks System regarding

Slide 25: Thank You
Thank You HEARTWARE, HVAD and the HEARTWARE logo are registered trademarks of HeartWare. Safe HeartWare® 25
Source: SEC EDGAR · 425 filed Nov 19, 2015
More decks from HeartWare International Inc
34th Annual J.P. Morgan Healthcare Conference (January 2016)35 slides · Jan 11, 2016
Proxy Contest (January 2016)7 slides · Jan 7, 2016
Oppenheimer 26th Annual Healthcare Conference 201525 slides · Dec 8, 2015
Credit Suisse 24th Annual Healthcare Conference 201530 slides · Nov 12, 2015
Merger or Acquisition (September 2015)42 slides · Sep 1, 2015
30th Annual J.P. Morgan Healthcare Conference (January 2012)22 slides · Jan 9, 2012